{"id":"https://openalex.org/W7202205578","doi":"https://doi.org/10.1016/j.jhepr.2026.101993","title":"EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE","display_name":"EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE","publication_year":2026,"publication_date":"2026-08-11","ids":{"openalex":"https://openalex.org/W7202205578","doi":"https://doi.org/10.1016/j.jhepr.2026.101993","pmid":"https://pubmed.ncbi.nlm.nih.gov/42580587","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13651485"},"language":"en","primary_location":{"id":"doi:10.1016/j.jhepr.2026.101993","doi":"https://doi.org/10.1016/j.jhepr.2026.101993","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jhepr.2026.101993","pdf_url":null,"source":{"id":"https://openalex.org/S4210202621","display_name":"JHEP Reports","issn_l":"2589-5559","issn":["2589-5559"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JHEP Reports","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.jhepr.2026.101993","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057424560","display_name":"Margarida Augusto","orcid":"https://orcid.org/0000-0002-2010-8284","observed_orcids":["https://orcid.org/0000-0002-2010-8284"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":true,"raw_author_name":"Margarida Augusto","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark. Electronic address: vmga@novonordisk.com"],"raw_orcid":"https://orcid.org/0000-0002-2010-8284","affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark. Electronic address: vmga@novonordisk.com","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137504329","display_name":"Robert Bauer","orcid":"https://orcid.org/0000-0003-2682-1125","observed_orcids":["https://orcid.org/0000-0003-2682-1125"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Robert Bauer","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":"https://orcid.org/0000-0003-2682-1125","affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5146537734","display_name":"Simon Clancy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126084","display_name":"Novo Nordisk (United Kingdom)","ror":"https://ror.org/0415cr103","country_code":"GB","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210126084","https://openalex.org/I4210159963"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon Clancy","raw_affiliation_strings":["Novo Nordisk Ltd., Gatwick, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk Ltd., Gatwick, United Kingdom","institution_ids":["https://openalex.org/I4210126084"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066143189","display_name":"Annemarie Poulsen","orcid":"https://orcid.org/0000-0003-4107-4818","observed_orcids":["https://orcid.org/0000-0003-4107-4818"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Aslak Sindbjerg Poulsen","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":"https://orcid.org/0000-0003-4107-4818","affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5120850788","display_name":"Fotis Tefos","orcid":"https://orcid.org/0009-0001-1037-1273","observed_orcids":["https://orcid.org/0009-0001-1037-1273"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Fotis Tefos","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064848842","display_name":"Michelle T. Long","orcid":"https://orcid.org/0000-0001-6131-3981","observed_orcids":["https://orcid.org/0000-0001-6131-3981"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Michelle Long","raw_affiliation_strings":["Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":"https://orcid.org/0000-0001-6131-3981","affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5057424560"],"corresponding_institution_ids":["https://openalex.org/I189090001"],"apc_list":{"value":4110,"currency":"USD","value_usd":4110},"apc_paid":{"value":4110,"currency":"USD","value_usd":4110},"fwci":6.6443,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.96801645,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"8","issue":"11","first_page":"101993","last_page":"101993"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9243000149726868,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9243000149726868,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.07180000096559525,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9279999732971191},{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/liver-fibrosis","display_name":"liver fibrosis","score":0.8230000138282776},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.8610000014305115},{"id":"https://openalex.org/keywords/eq-5d-utility","display_name":"EQ-5D utility","score":0.8270000219345093},{"id":"https://openalex.org/keywords/sf-36","display_name":"SF-36","score":0.7279999852180481},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.6769999861717224},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8059999942779541},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.7870000004768372},{"id":"https://openalex.org/keywords/essence-trial","display_name":"ESSENCE trial","score":0.8790000081062317},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.5149999856948853},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.7549999952316284},{"id":"https://openalex.org/keywords/utility-mapping","display_name":"utility mapping","score":0.4309999942779541},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.6014999747276306},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.33230000734329224},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2980000078678131},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.2590999901294708},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.2493000030517578},{"id":"https://openalex.org/C3018122547","wikidata":"https://www.wikidata.org/wiki/Q5690813","display_name":"Health benefits","level":2,"score":0.2467000037431717},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.24570000171661377},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.24390000104904175},{"id":"https://openalex.org/C61797465","wikidata":"https://www.wikidata.org/wiki/Q1188986","display_name":"Term (time)","level":2,"score":0.23980000615119934},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.2345999926328659}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1016/j.jhepr.2026.101993","doi":"https://doi.org/10.1016/j.jhepr.2026.101993","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jhepr.2026.101993","pdf_url":null,"source":{"id":"https://openalex.org/S4210202621","display_name":"JHEP Reports","issn_l":"2589-5559","issn":["2589-5559"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JHEP Reports","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13651485","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JHEP Rep","raw_type":"Text"},{"id":"pmid:42580587","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42580587","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JHEP reports : innovation in hepatology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:064bf8ee3d3a442895431a2549ed9a17","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/064bf8ee3d3a442895431a2549ed9a17","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"JHEP Reports, Vol 8, Iss 11, Pp 101993- (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.jhepr.2026.101993","doi":"https://doi.org/10.1016/j.jhepr.2026.101993","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jhepr.2026.101993","pdf_url":null,"source":{"id":"https://openalex.org/S4210202621","display_name":"JHEP Reports","issn_l":"2589-5559","issn":["2589-5559"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JHEP Reports","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1972932269","https://openalex.org/W4200445982","https://openalex.org/W4205944655","https://openalex.org/W4309348832","https://openalex.org/W4365482992","https://openalex.org/W4387640319","https://openalex.org/W4401712318","https://openalex.org/W4404816270","https://openalex.org/W4407243431","https://openalex.org/W4409963211"],"related_works":["https://openalex.org/W7154625292","https://openalex.org/W4414963742","https://openalex.org/W4415041542","https://openalex.org/W7223249101","https://openalex.org/W7106659599","https://openalex.org/W4415603825","https://openalex.org/W4417241148","https://openalex.org/W7164379232","https://openalex.org/W4412436744","https://openalex.org/W7166096405"],"abstract_inverted_index":{"BACKGROUND":[0],"&":[1],"AIMS:":[2],"Metabolic":[3],"dysfunction-associated":[4,13,271],"steatohepatitis":[5,272],"(MASH)":[6,273],"is":[7,18],"the":[8,42,61,69,135,251,317,332,342,345],"progressive":[9],"form":[10],"of":[11,33,71,121,254,320,323,334],"metabolic":[12,270],"steatotic":[14],"liver":[15],"disease.":[16],"It":[17],"highly":[19],"prevalent,":[20],"particularly":[21],"among":[22],"individuals":[23],"with":[24,50,99,146,195,204,217,262,269,297,350],"overweight":[25],"or":[26,106,117,208],"obesity,":[27],"and":[28,53,102,151,157,206,241,274,283,311,341],"substantially":[29],"impairs":[30],"health-related":[31,318],"quality":[32,319],"life.":[34],"Semaglutide":[35],"2.4":[36,115,213,265,299],"mg":[37,116,214,266,300],"received":[38],"accelerated":[39],"approval":[40],"from":[41,60,87,129,142],"US":[43],"FDA":[44],"in":[45,76,170,221,267,292],"August":[46],"2025":[47],"for":[48,281],"adults":[49,203],"noncirrhotic":[51],"MASH":[52,101,205],"fibrosis":[54,103,152,199],"stages":[55,153],"F2-F3":[56],"based":[57],"on":[58,73],"results":[59,305,346],"ESSENCE":[62,88],"trial.":[63,97],"This":[64,80,248],"study":[65,249],"aimed":[66],"to":[67,111,237],"estimate":[68],"impact":[70],"semaglutide":[72,114,176,212,264,298,324],"health":[74,224,242,258,295],"utility":[75,166,181,225,232,259,296],"this":[77],"population.":[78],"METHODS:":[79],"exploratory":[81,229],"analysis":[82],"used":[83],"Week":[84,174],"72":[85,302],"data":[86],"Part":[89],"1,":[90],"a":[91,288,326],"Phase":[92],"III,":[93],"randomized,":[94],"double-blind,":[95],"placebo-controlled":[96],"Adults":[98],"biopsy-confirmed":[100],"stage":[104],"F2":[105,207],"F3":[107,209],"were":[108,127],"randomized":[109],"2:1":[110],"once-weekly":[112,211,263],"subcutaneous":[113],"placebo":[118,183],"plus":[119],"standard":[120],"care.":[122],"EuroQol":[123,255],"5-\u200dDimension":[124],"(EQ-5D)":[125,257],"utilities":[126,340],"mapped":[128,164,179,222,293,335],"Short":[130],"Form-36":[131],"(SF-36)":[132],"scores":[133],"using":[134,325],"Rowen":[136],"et":[137],"al.":[138],"(2009)":[139],"algorithm.":[140],"Change":[141],"baseline":[143,148],"was":[144,167,215],"analyzed":[145],"treatment,":[147],"diabetes":[149],"status,":[150],"as":[154],"covariates.":[155],"RESULTS:":[156],"55.9%":[158],"had":[159],"type":[160],"2":[161],"diabetes.":[162],"Baseline":[163],"EQ-5D":[165,180,223,294],"approximately":[168],"0.78":[169],"both":[171],"groups.":[172],"At":[173],"72,":[175],"significantly":[177],"improved":[178],"vs.":[182,226],"(estimated":[184],"treatment":[185],"difference":[186],"0.03;":[187],"95%":[188],"CI":[189],"0.01-0.06;":[190],"nominal":[191],"p":[192],"=":[193],"0.0015),":[194],"consistent":[196],"effects":[197],"across":[198],"stages.":[200],"CONCLUSIONS:":[201],"In":[202],"fibrosis,":[210],"associated":[216,261],"statistically":[218,289],"significant":[219,290],"improvements":[220],"placebo.":[227],"These":[228,304],"findings":[230,278],"provide":[231],"estimates":[233,253],"that":[234],"may":[235],"help":[236],"inform":[238,308],"cost-effectiveness":[239,309],"evaluations":[240],"technology":[243],"assessments.":[244],"IMPACT":[245],"AND":[246],"IMPLICATIONS:":[247],"provides":[250],"first":[252],"5-Dimension":[256],"gains":[260],"people":[268],"F2/F3":[275],"fibrosis.":[276],"The":[277],"are":[279],"important":[280],"payers":[282],"clinicians":[284],"because":[285],"they":[286],"demonstrate":[287],"improvement":[291],"over":[301],"weeks.":[303],"can":[306],"directly":[307,338],"models":[310],"support":[312],"healthcare":[313],"decision-making":[314],"by":[315],"quantifying":[316],"life":[321],"benefits":[322],"widely":[327],"accepted":[328],"preference-based":[329],"metric.":[330],"Given":[331],"use":[333],"rather":[336],"than":[337],"measured":[339],"UK-specific":[343],"tariff,":[344],"should":[347],"be":[348],"interpreted":[349],"appropriate":[351],"caution.":[352]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-08-12T00:00:00"}